Open AccessInability of Plasma and Urine F2A-Isoprostane Levels to Differentiate Mild Cognitive Impairment from Alzheimer’s Disease
Author(s) -
Elliott J. Mufson,
Sue E. Leurgans
Publication year - 2010
Publication title -
neurodegenerative diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.98
H-Index - 57
eISSN - 1660-2862
pISSN - 1660-2854
DOI - 10.1159/000289224
Subject(s) - urine , dementia , biomarker , isoprostane , medicine , alzheimer's disease , cognitive impairment , oxidative stress , disease , urinary system , lipid peroxidation , endocrinology , chemistry , biochemistry
Oxidative stress has been implicated in the pathogenesis of Alzheimer's disease (AD). The pathobiological changes related to AD occur long before the overt clinical symptoms. The plasma lipid peroxidation enzyme F2-isoprostane has been suggested as a biomarker to detect the progression from mild cognitive impairment (MCI) to AD.